SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
Granted FDA Fast Track Designation for APC Clinical Candidate Published Comprehensive Preclinical Research on SQZ® TAC Platform in Frontiers in Immunology Presented First SQZ® Point-of-Care (POC) Manufacturing System Performance Data; Initial Clinical Use Planned for SQZ® TAC Celiac Disease Program with IND Submission Expected in First Half 2023 Strengthened Leadership with Experienced CMO and CFO … [Read more…]
